Von Hippel Lindau tumor suppressor controls m6A-dependent gene expression in renal tumorigenesis
Journal of Clinical Investigation · 15.04.2024 · 134 (8)
DOI: 10.1172/jci175703 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 15.04.2024. Verfasst von Cheng Zhang und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, USA. Hauptthemen laut MEDLINE: Adenine, Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIGMS NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
N6-Methyladenosine (m6A) is the most abundant posttranscriptional modification, and its contribution to cancer evolution has recently been appreciated. Renal cancer is the most common adult genitourinary cancer, approximately 85% of which is accounted for by the clear cell renal cell carcinoma (ccRCC) subtype characterized by VHL loss. However, it is unclear whether VHL loss in ccRCC affects m6A patterns. In this study, we demonstrate that VHL binds and promotes METTL3/METTL14 complex formation while VHL depletion suppresses m6A modification, which is distinctive from its canonical E3 ligase role. m6A RNA immunoprecipitation sequencing (RIP-Seq) coupled with RNA-Seq allows us to identify a selection of genes whose expression may be regulated by VHL-m6A signaling. Specifically, PIK3R3 is identified to be a critical gene whose mRNA stability is regulated by VHL in a m6A-dependent but HIF-independent manner. Functionally, PIK3R3 depletion promotes renal cancer cell growth and orthotopic tumor growth while its overexpression leads to decreased tumorigenesis. Mechanistically, the VHL-m6A–regulated PIK3R3 suppresses tumor growth by restraining PI3K/AKT activity. Taken together, we propose a mechanism by which VHL regulates m6A through modulation of METTL3/METTL14 complex formation, thereby promoting PIK3R3 mRNA stability and protein levels that are critical for regulating ccRCC tumorigenesis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
- Lineberger Comprehensive Cancer Center, University of North Carolina (UNC) School of Medicine, Chapel Hill, North Carolina, USA.
- Department of Genetics, Neuroscience Center and.
- UNC Neuroscience Center, Carolina Institute for Developmental Disabilities, UNC, Chapel Hill, North Carolina, USA.
- Department of Molecular Medicine, Mays Cancer Center, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.
- Department of Biochemistry, Department of Biophysics, Simmons Comprehensive Cancer Center and.
Förderung
- NCI NIH HHS
- NIGMS NIH HHS
- National Cancer Institute
Zitieren
APA
Zhang, C., Yu, M., Hepperla, A. J., Zhang, Z., Raj, R., Zhong, H., Zhou, J., Hu, L., Fang, J., Liu, H., Liang, Q., Jia, L., Liao, C., Xi, S., Simon, J. M., Xu, K., Liu, Z., Nam, Y., Kapur, P., & Zhang, Q. (2024). Von Hippel Lindau tumor suppressor controls m6A-dependent gene expression in renal tumorigenesis. Journal of Clinical Investigation, 134(8). https://doi.org/10.1172/jci175703
Vancouver
Zhang C, Yu M, Hepperla AJ, Zhang Z, Raj R, Zhong H, et al. Von Hippel Lindau tumor suppressor controls m6A-dependent gene expression in renal tumorigenesis. Journal of Clinical Investigation. 2024;134(8). doi:10.1172/jci175703
BibTeX
@article{Zhang2024,
author = {Zhang, Cheng and Yu, Miaomiao and Hepperla, Austin J and Zhang, Zhao and Raj, Rishi and Zhong, Hua and Zhou, Jin and Hu, Lianxin and Fang, Jun and Liu, Hongyi and Liang, Qian and Jia, Liwei and Liao, Chengheng and Xi, Sichuan and Simon, Jeremy M and Xu, Kexin and Liu, Zhijie and Nam, Yunsun and Kapur, Payal and Zhang, Qing},
title = {Von Hippel Lindau tumor suppressor controls m6A-dependent gene expression in renal tumorigenesis},
journal = {Journal of Clinical Investigation},
year = {2024},
volume = {134},
number = {8},
doi = {10.1172/jci175703}
}
EUVIMED